San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Cellics Therapeutics is raising $13,000,635.00 in new funding. Sources indicate as part of senior management Chief Operating Officer, Huiqing Zhu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cellics Therapeutics

The mission of Cellics is to employ innovative biomimetic nanomedicines to address serious diseases with a high unmet medical need. The company’s initial primary focus is on autoimmune and inflammatory diseases and difficult to treat infectious diseases. Additionally, Cellics is seeking to develop best-in-class vaccines for various diseases. The company is currently on schedule to advance its lead product candidate CTI-005 to human clinical trials for the treatment of bacterial pneumonia. It is the passion and goal of Cellics to use advanced technology to help human beings live healthier and longer lives.

To learn more about Cellics Therapeutics, visit http://cellics.com/

Contact:
Huiqing Zhu, Chief Operating Officer
858-357-6386

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved